A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.
Australian stocks are soaring as the first interest rate cut looms but value is far from universal as the market nears record ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback